Post Vaccination – Vaccine Targeted Strain – Viral and Bacterial Pathogen – Shedding
So how much of this said claim is truth and real, and/or not real? Do we know? A search for the evidence.
First of all, let me ask this. Why is it, that when the conclusions of actually peer reviewed studies are not in your favor as to the intended agenda bias, that even endless peer reviewed studies are not enough to get pro-vaccine people to take a look at and even read a single one of those studies; yet when there are limited to little to no existing peer reviewed studies, that they are jumping all over with demands to produce a peer reviewed study, to make such as any certain such as a vax-truth opposing persons point of contention, that has expressed?
In regard to vaccines lets go to the issue of vaccine shedding, and ask the question as to can and do any of the current vaccines shed the pathogen in a way that could make a non vaccinated person susceptible to acquiring the illness from a vaccinated person. There are in Pubmed several but limited studies that address the shedding issue as to in regard to the various vaccines. Just use the search terms vaccine shedding Pubmed, and will you several but as said limited numbers references in the google listing, and then you can go to pubmed itself, which is somewhat as well limited for available references as to claiming one way or the other. As for the measles vaccine, one Pubmed reference stated that it the vaccine could shed for up to three days. Certainly long enough to infect another individual.
So, actually and possibly no one really nor likely knows for sure what the complete truth is on this issue. It would seem to be common sense that the vaccine makers surely do not and would not want to know if their vaccine causes shedding or not; nor to find out. So then who would actually fund theses said studies. I think with what I read and reviewed in regard to vaccine shedding, just getting into even the beginning phase of the studies, tells me that vaccines do have a potential to shed irregardless of being bacterial or viral; which very well could be an obvious risk to the unvaccinated. I mean good grief, the existing studies clearly point to the push to vaccinate everyone due to the risk of shedding possibility. What more evidence would you need of the risk of the vaccinated, to the unvaccinated? And yet the pro-vaccine side wants to claim to just the opposite; and that it is only the vaccinated that are at risk from the unvaccinated??? You know accused again of reducing the vaccine derived herd immunity; even though the schools most often even today have no more than a 5% or less rate of existing school exemptions? We as well by the way are not are NOT just talking about the oral polio vaccine, here. They clearly know that the oral polio vaccine sheds and can as well cause numerous cases of AFP in the underdeveloped and unsanitary for conditions countries, that the oral polio vaccine is still used to day. They know of the identified mutations in the polio vaccine virus that the the said oral vaccine has very likely as well caused. if they have an alternative explanation, I have yet to hear and or read about it.
So, let me ask you, have vaccines eradicated so called illness and disease, or have they just prolonged the exit, while creating only lower levels of chronic disease, and disease conditions? How about other unrelated chronic illness and autoimmune disease, unrelated to the vaccine targeted pathogen? How about the pubmed listed as well references to the harm of aluminum adjuvants, causing overactivation of the brains microglia and resulting low levels of chronic brain inflammation resulting for repeat multiple vaccines, in some individuals; maybe more individuals and children that we have ever realized? How about the aluminum adjuvant connection to ASD? The studies, and new studies have shown that same brain inflammation to now be found in more and more children and individuals with ASD. And they want to tell us that vaccines have never been scientifically linked in any study, to ASD? Really? How about the MMR vaccine, in which there are actually some similar physiological pathways found in relation to ASD, and also which are in common with heavy metal toxicity, if not overload, in regard to both thimerosal, and aluminum adjuvants. I don’t know about you and what you think, but I think it is not looking good for the claim as to the issue of vaccines doing more good than harm. When will the CD stop living in the dark ages, and dragging their feet as to doing the proper studies? Yet they waste millions chasing the genetic link to ASD, and refuse all other types and forms of real research?
I did pick one specific peer reviewed reference in regard shedding, that I thought was interesting, and a bit troublesome regarding risk. In regard to the shedding of course all they can come up with is to come up with that every last person existing must be vaccinated to protect them against the shedding.
Pertussis infection in fully vaccinated children in day-care centers, Israel.
Abstract
We tested 46 fully vaccinated children in two day-care centers in Israel who were exposed to a fatal case of pertussis infection. Only two of five children who tested positive for Bordetella pertussis met the World Health Organization’s case definition for pertussis. Vaccinated children may be asymptomatic reservoirs for infection.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627963/
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2627963/pdf/10998384.pdf
Pertussis Vaccine Failure is not Just Modern but Historical: Vaccine has Never Been Effective
http://healthimpactnews.com/2013/pertussis-vaccine-failure-is-not-just-modern-but-historical-vaccine-has-never-been-effective/
Researchers find first US evidence of vaccine-resistant pertussis
http://healthimpactnews.com/2013/researchers-find-first-us-evidence-of-vaccine-resistant-pertussis/
And they tell us the vaccines do not shed? How would this be possible if the vaccines do not shed anything contagious? And they want us to believe that the un-vaccinated are a risk to the vaccinated. Vaccine derived herd relatively and comparatively short term immunity, has never had any actual science behind it; and as to natural long term and/or life time immunity, where as that concept actually makes does sense. So what is the REAL reason they say they need vaccine derived herd immunity? Is it possible that it is more likely due to the issue of vaccine shedding? Now we are getting to some actual understanding of what possibly really goes on.
17 Examples of Admitted Vaccine Failure
http://vactruth.com/2013/02/23/17-examples-of-vaccine-failure/
Article
ECZEMA VACCINATUM
ABSTRACT
Nine cases of eczema vaccinatum are presented, including two fatalities. Seven were caused by contact of a child with eczema with a recently vaccinated sibling.
Suddenly appearing umbilicated vesicles superimposed upon atopic eczema are almost diagnostic of eczema vaccinatum or eczema herpeticum. These do not occur with mere secondary bacterial infection.
Hyperimmune vaccinal gamma-globulin is now available for specific therapy.
Eczema vaccinatum is frequently iatrogenic and uniformly preventable.
The following steps are recommended for prophylaxis: 1) No child with atopic eczema or other skin disorder should be vaccinated. 2) No child should be vaccinated if any member of his family has eczema or other skin disorder. 3) Parents of children with eczema should be notified at the onset of the disease of the danger from vaccination contact. 4) If a sibling of a child with atopic eczema is vaccinated, he must be completely separated from that child for at least 21 days. 5) Forms used by state and local health departments for parents’ consent to vaccination should include an appropriate warning of the contraindications. 6) Eczema vaccinatum should be a reportable disease. 7) Patients recently vaccinated must be excluded from pediatric wards containing patients with atopic eczema, other diseases of the skin, burns or healing surgical incisions. 8) Vaccination may be recommended at 2 months of age, especially for babies from strongly allergic families.
http://pediatrics.aappublications.org/content/22/2/259
Acellular pertussis vaccination enhances B. parapertussis colonization
An acellular whooping cough vaccine actually enhances the colonization of Bordetella parapertussis in mice; pointing towards a rise in B. parapertussis incidence resulting from acellular vaccination, which may have contributed to the observed increase in whooping cough over the last decade.
http://www.cidd.psu.edu/research/synopses/acellular-vaccine-enhancement-b.-parapertussi
And rarely are they testing for it nor even knowing understanding what pertussis pathogen strains are there. B parapertussis antigen is not in the current vaccine. And the fear mongering and the recommended boosters continue.
They can admit to the pertussis vaccine failure in Pakistan, but the CDC can not and refuses to admit to that here happening in the US.
Public Health. 2012 Jun;126(6):518-22. doi: 10.1016/j.puhe.2012.02.001. Epub 2012 Mar 23.
Pertussis resurgence among vaccinated children in Khairpur, Sindh, Pakistan.
Mughal A, Kazi YF, Bukhari HA, Ali M.
Source:Diagnostic and Research Centre, Department of Microbiology, Shah Abdul Latif University, Khairpur, Sindh, Pakistan.
Abstract
OBJECTIVES:
To investigate the aetiology of persistent cough among vaccinated children as suspected cases of pertussis in Khairpur District, Sindh, Pakistan. Pertussis or whooping cough, caused by Bordetella pertussis, is re-appearing in many countries despite vaccination coverage. In Khairpur, persistent cough and symptoms similar to pertussis among vaccinated children are common but the aetiology has not been investigated previously.
STUDY DESIGN:
B. pertussis was isolated from cough samples of suspected pertussis patients (n = 700) using the cough plate method with charcoal agar.
METHODS:
Isolation and confirmation of the clinical isolates of B. pertussis was performed by culture on Bordet-Gengou medium, biochemical tests and polymerase chain reaction.
RESULTS:
In total, 22 strains of B. pertussis were isolated from clinical cough samples.
CONCLUSION:
To the authors’ knowledge, this is the first report of the presence of pertussis in vaccinated children in Khairpur. There is a need for continuous monitoring of pertussis after immunization programmes in order to assess the efficacy of pertussis vaccination.
http://www.ncbi.nlm.nih.gov/pubmed/22445714
And what has the CDC done about it all? They have only continued with their fear mongering and falsely blaming the un-vaccinated. Cocoon tyle vaccinating whole families, and still the outbreaks occur.
The False Theory of Vaccine Derived – Herd Immunity
http://www.vacfacts.info/the-false-theory-of-vaccine-derived—herd-immunity.html
———————-
Whooping Cough Epidemic Caused by Virulent New Pertussis Strain—And It’s the Result of Vaccine
http://gaia-health.com/gaia-blog/2012-10-31/whooping-cough-epidemic-caused-by-virulent-new-pertussis-strain-and-its-the-result-of-vaccine/
Bordetella pertussis Strains with Increased Toxin Production Associated with Pertussis Resurgence (PDF)
Abstract excerpt:
We present evidence that in the Netherlands the dramatic increase in pertussis is temporally associated with the emergence of Bordetella pertussis strains carrying a novel allele for the pertussis toxin promoter, which confers
increased pertussis toxin (Ptx) production. Epidemiologic data suggest that these strains are more virulent in humans. We discuss changes in the ecology of B. pertussis that may have driven this adaptation. Our results underline the importance of Ptx in transmission, suggest that vaccination may select for increased virulence, and indicate ways to control
http://gaia-health.com/articles451/000485-bpertussis.pdf
J Hyg (Lond). 1976 August; 77(1): 85–91.
PMCID: PMC2129724
Prevalent serotypes of Bordetella pertussis in non-vaccinated communities.
Abstract
In many countries, the prevalent serotypes of Bordetella pertussis have changed from a mixture of types 1,2,3 and 1,2 (organisms possessing antigen 2) to a predominance of type 1,3. The timing of the change in different countries is shown to be related to the introduction of mass-vaccination with material rich in antigens 1 and 2 but weak in, or devoid of, antigen 3. In several parts of the world, there have been outbreaks of type 1,3 infection in fully vaccinated children. Non-vaccinated communities in various parts of the world still show the pattern of serotypes which existed elsewhere before mass-vaccination. In order to avoid the disappointments experienced in the past, it is essential that pertussis vaccine for use in previously non-vaccinated communities, like that for any other country, should be rich in each of the three antigens.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2129724/
RESEARCH ARTICLE
Small Mutations in Bordetella pertussis Are Associated with Selective Sweeps
Abstract excerpt:
Our results suggest that the B. pertussis gene repertoire is already well adapted to its current niche and required only fine tuning to persist in the face of vaccination. Further, this work shows that small mutations, even single SNPs, can drive large changes in the populations of bacterial pathogens within a time span of six to 19 years.
http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0046407
You can not patent vitamin C, as you can an expensive drug or vaccine. Modern medicine is NOT about the actual health of your child, unless it can be done with chemical pharma.
Special Report: The Vitamin C Treatment of Whooping Cough (Pertussis)
Here is what they already knew years ago in the treatment of pertussis.
Can Med Assoc J. 1937 August; 37(2): 134–136.
PMCID: PMC1562195
Ascorbic Acid (Vitamin C) Treatment of Whooping Cough *
Discussion
The short series of cases presented is too small to draw any statistical conclusions, but one fact stands out. Ascorbic acid has a definite efTect in shortening the period of paroxysms from a matter of weeks to a matter of days. We have not checked by cough plates or otherwise in this preliminary work to see whether the infectivity subsides simultaneously with the spasmodic symptoms, but are continuing with a larger series of cases in which these and other tests will be employed.
The dosages used have been empirical, with a tendency to use larger doses early in the disease as our experience of its effects progressed. The acid is available at reasonable prices, and the danger of overdosage seems negligible. Animals have received 2,000 times their estimated requirements without any deleterious effects. Any excess is excreted by the kidneys.
CONCLUSIONS
1. A method has been described for the treatment of whooping cough by ascorbic acid
(vitamin C).
2. Ascorbic acid definitely shortens the paroxysmal stage of the disease, particularly if
relatively
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1562195/?page=3
Pertussis is a bacteria, but either way it is beneficial.
Vitamin C As An Antiviral: It’s All About Dose
http://orthomolecular.org/resources/omns/v05n09.shtml
Vitamin C for Whooping Cough. Updated Edition. Suzanne Humphries, MD
http://www.vaccinationcouncil.org/2012/09/07/vitamin-c-for-whooping-cough-updated-edition-suzanne-humphries-md/
Why is nobody studying vitamin C in whooping cough? – Conventional medicine’s hypocrisy. by Suzanne Humphries, MD
http://www.vaccinationcouncil.org/2012/08/03/why-is-nobody-studying-vitamin-c-in-whooping-cough-by-suzanne-humphries-md/
LIPOSOMAL ENCAPSULATED VITAMIN C
http://www.vacfacts.info/anti-viral—liposomal-encapsulated-vitamin-c.html
————————————-
History Repeats Itself: Lessons Vaccinators Refuse to Learn, by Jennifer Craig, PhD
http://www.vaccinationcouncil.org/2012/04/17/history-repeats-itself-lessons-the-vaccinationists-refuse-to-learn-by-jennifer-craig-phd/
Another below is another example of a failed effort with polio vaccine. It does little good to claim to have eliminated a certain number of previously present cases of polio, while at the same time causing massive cases of polio vaccine derived paralysis. 47,500 new cases. Yet they claim this is NECESSARY, to eradicate polio. They refuse to admit any failure, it seems to me?
Indian J Med Ethics. 2012 Apr-Jun;9(2):114-7.
Polio programme: let us declare victory and move on.
Vashisht N, Puliyel J.
Source:Department of Paediatrics, St Stephens Hospital, Delhi 110054, India.
Abstract
It was hoped that following polio eradication, immunisation could be stopped. However the synthesis of polio virus in 2002, made eradication impossible. It is argued that getting poor countries to expend their scarce resources on an impossible dream over the last 10 years was unethical. Furthermore, while India has been polio-free for a year, there has been a huge increase in non-polio acute flaccid paralysis (NPAFP). In 2011, there were an extra 47,500 new cases of NPAFP. Clinically indistinguishable from polio paralysis but twice as deadly, the incidence of NPAFP was directly proportional to doses of oral polio received. Though this data was collected within the polio surveillance system, it was not investigated. The principle of primum-non-nocere was violated. The authors suggest that the huge bill of US$ 8 billion spent on the programme, is a small sum to pay if the world learns to be wary of such vertical programmes in the future.
http://www.ncbi.nlm.nih.gov/pubmed/22591873
VIDS – Vaccine Induced Diseases
http://www.vaccinesuncensored.org/vids.php
51 035 cases of AFP appear in this document (p 578) for India in 2011, and the in 2011. The figure of 86 638 cases of AFP was listed as globally.
http://www.who.int/wer/wer8650.pdf
VRM: The Re-emergence of Polio in The Third World (compliments of the World Health Organization & Bill Gates)
http://vaccineresistancemovement.org/?p=10091
VRM: Weaponized Polio & The African Green Monkey Conundrum
http://vaccineresistancemovement.org/?p=10727
Why I choose not to Vaccinate my child
by: Amy Goalen Whittam
https://docs.google.com/document/pub?id=1Y2hS7WxS2gU4yXCjuYx84AY60tQc2rGXnTPPWqogOfk
What Is Coming Through That Needle? The Problem of Pathogenic Vaccine Contamination
Benjamin McRearden
http://www.scribd.com/doc/42722540/Vaccine-Contamination-Mcrearden
Mutant Polio Virus Spreads in Nigeria
Experts have long believed epidemics unleashed by a vaccine’s mutated virus wouldn’t last since the vaccine only contains a weakened virus strain – but that assumption is coming under pressure. Some experts now say that once viruses from vaccines start circulating they can become just as dangerous as wild viruses.
“The only difference is that this virus was originally in a vaccine vial,” said Olen Kew, a virologist at the U.S. Centers for Disease Control and Prevention.
The oral polio vaccine used in Nigeria and elsewhere contains a mild version of the live virus. Children who have been vaccinated pass the virus into the water supply through urine or feces. Other children who then play in or drink that water pick up the vaccine’s virus, which gives them some protection against polio.
But in rare instances, as the virus passes through unimmunized children, it can mutate into a strain dangerous enough to ignite new outbreaks, particularly if immunization rates in the rest of the population are low.
Kew said genetic analysis proves mutated viruses from the vaccine have caused at least seven separate outbreaks in Nigeria.
Though Nigeria’s coverage rates have improved, up to 15 percent of children in the north still haven’t been vaccinated against polio. To eradicate the disease, officials need to reach about 95 percent of the population.
Nigeria’s vaccine-linked outbreak underlines the need to stop using the oral polio vaccine as soon as possible, since it can create the very epidemics it was designed to stop, experts say. WHO is researching other vaccines that might work better, but none is on the horizon.
Until a better vaccine is ready, WHO and U.S. CDC officials say the oral vaccine is the best available tool to eradicate polio and that when inoculation rates are nearly 100 percent it works fine.
“Nigeria is almost a case study in what happens when you don’t follow the recommendations,” Kew said.
http://www.cbsnews.com/2100-204_162-5242168.html
Mutated Polio From Vaccine Is Spreading in Africa
A mutation from a live polio vaccine is stalking Nigeria. In a strange twist of logic, experts are claiming that it mutated as it passed through non-immunized children.
The claim is that children given the live attenuated oral vaccine are properly immunized, but the live virus passes through them and enters local water supplies through their urine or feces. Then, children who have not been immunized pick up the supposedly safe virus by drinking or playing in the water. The weakened virus mutates in them, becoming a new virulent strain.
Why the virus would choose to mutate in non-vaccinated, rather than vaccinated, children is unexplained. Even odder is why the weakened virus would pass through the vaccinated children. If the purpose of a live attenuated vaccination is to force the body to develop antibodies to the virus, then why would live viruses be excreted? Shouldn’t they be killed by the newly-developed antibodies?
Are we being lied to?
This sounds much like the argument that blames nonvaccinated people for disease in those who’ve submitted to innoculations. If the vaccines are effective, then why would the vaccinated be at risk from the unvaccinated?
Are we being lied to?
http://www.gaia-health.com/articles51/000078-Polio-Caused-By-Vaccine.shtml
Nigeria Sees Polio Outbreak from Mutated Vaccine Virus
http://www.pbs.org/newshour/updates/health/july-dec09/polio_08-24.html
Polio in Nigeria Traced to Mutating Vaccine
http://www.nytimes.com/2007/10/11/world/africa/11polio.html?_r=0
Mutated virus confirms polio vaccine fears. New Delhi
http://www.telegraphindia.com/1101024/jsp/nation/story_13094132.jsp
Vaccine. 1994 May;12(6):503-7.
Point mutations involved in the attenuation/neurovirulence alternation in type 1 and 2 oral polio vaccine strains detected by site-specific polymerase chain reaction.
We screened for this mutation in five type 1 and nine type 2 polio vaccine-derived strains isolated from vaccine-associated paralytic poliomyelitis (VAPP) cases and in 16 such strains isolated from healthy vaccinees. All 14 strains isolated from VAPP presented the reversion. Of the eight pairs of type 1 isolates from healthy vaccinees, four presented the reversion 3 days after vaccine administration and all but one at 7 days postvaccination. These results support the involvement of the 5′ non-coding specific nucleotide sites in the reversion to neurovirulence of attenuated polio vaccine strains upon multiplication in the human gut
http://www.ncbi.nlm.nih.gov/pubmed/8036823
Look at the unbelievable statements in the next set of information. So ask, WHY are they using a live and shedding viral vaccine, in these contaminated areas, at all?
Oral Polio Vaccine Circulation and Mutation after Mexican National Immunization Weeks
Conclusion: OPV, primarily serotype 2, was detected in sewage as late as 7 months after an NIW in a Mexican community primarily vaccinated with IPV, but was not detected at 8 months, suggesting that OPV circulation may have ceased. VAPP mutants were predominantly detected. This data suggests that in communities with high vaccination rates, one or two years of IPV administration after OPV cessation could be sufficient to prevent outbreaks of paralytic poliomyelitis from vaccine-derived strains.
https://idsa.confex.com/idsa/2011/webprogram/Paper30468.html
Polio vaccine suspected as cause of fatal mutant form of encephalitis
The polio vaccine isn’t protecting children – and, worse, it appears to be causing a new and sometimes fatal form of the disease.
Concerns about the vaccine have arisen following a high number of deaths and hospital admissions from encephalitis and polio in the Uttar Pradesh region of India – where there has been an intensive vaccination programme.
Around 400 children have died, and a further 2,300 admitted to hospital, following an outbreak of a new form of viral encephalitis, and doctors admit they do not know its cause.
http://www.wddty.com/polio-vaccine-suspected-as-cause-of-fatal-mutant-form-of-encephalitis.html
Unvaccinated Blamed for Mutated Polio, (AGAIN ALWAYS FALSELY THE UNVACCINATED ARE BLAMED FOR ANYTHING THAT HAPPENS)
Mutant polio vaccine regains virulence
Excerpts:
But the latest study raises the frightening possibility that the vaccine strain can also regain the ability to spread between people more easily than thought. “It demonstrates clearly that the vaccine virus can spread from person to person,” says Olen Kew from the Centers for Disease Control and Prevention in Atlanta, Georgia.
The outbreak was exacerbated by the fact that Haiti had relaxed its polio vaccination program more than five years earlier. “It’s a warning that you need to have good coverage to prevent vaccines from running away like this,” Kew says.
Total eradication
The study also shows how difficult it will be eliminate polio entirely. For this to be achieved, natural polio would first have to be wiped out through stringent use of the oral polio vaccine. Then all countries could simultaneously stop vaccinating or switch to a different vaccine – injectable, dead polio virus.
This method does not confer as much immunity as the oral vaccine, but it cannot revert to a disease-causing form. This vaccine is already used in the US and much of Europe.
http://www.newscientist.com/article/dn2047-mutant-polio-vaccine-regains-virulence.html
This again points to the claim that they think they need to get 100% vaccine coverage in ever country with existing polio, and only then it may be possible to stop polio, but yet they know they will have the mutations still going on and the result of that is in their minds quite obviously only necessary collateral damage, so to speak. So, as long as they can keep blaming it all on the unvaccinated, which is not exactly proven; it is an assumption. And as long as they keep playing Russian Roulette with the vaccine virus; in the hopes that it does not continue to mutate to a point of becoming a super virus world wide. But in the end, the with the known odds that have been and in the resulting outcomes; clearly it all shows this plan to be not only failing and dangerous; but even currently, is likely causing more harm than good; and will continue to.
J Clin Microbiol. 1995 Sep;33(9):2485-8.
Detection of measles virus RNA in urine specimens from vaccine recipients.
Rota PA, Khan AS, Durigon E, Yuran T, Villamarzo YS, Bellini WJ.
Source: Division of Viral and Rickettsial Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
Abstract
Analysis of urine specimens by using reverse transcriptase-PCR was evaluated as a rapid assay to identify individuals infected with measles virus. For the study, daily urine samples were obtained from either 15-month-old children or young adults following measles immunization. Overall, measles virus RNA was detected in 10 of 12 children during the 2-week sampling period. In some cases, measles virus RNA was detected as early as 1 day or as late as 14 days after vaccination. Measles virus RNA was also detected in the urine samples from all four of the young adults between 1 and 13 days after vaccination. This assay will enable continued studies of the shedding and transmission of measles virus and, it is hoped, will provide a rapid means to identify measles infection, especially in mild or asymptomatic cases.
http://www.ncbi.nlm.nih.gov/pubmed/7494055
You see in the next below link that it ALL depends on who has done the study, as for if they find the evidence of shedding due to a/or the vaccine. Here we have the Journal of Infectious diseases that is closely aligned with pharma and Offit’s CHOP. And they of course find predicable no shedding. Can you imagine the upset if they had, and presented to the CDC with that? Clearly, is not happening.
J Infect Dis. 2004 May 1;189 Suppl 1:S165-70.
Lack of evidence of measles virus shedding in people with inapparent measles virus infections.
http://www.ncbi.nlm.nih.gov/pubmed/15106106
And here, and again pharma connected
http://www.ncbi.nlm.nih.gov/pubmed/22983013
So, the pro vaccine side again claims to what? Well if there are no studies to prove that the vaccines cause shedding, then it simply doesn’t happen. Just like in regard to the vaccine aluminum adjuvants; if no studies have ever been done, then we can proclaim that there is no scientific proof of the harm, thus there is no said harm being done.
J Clin Microbiol. 2008 Mar;46(3):1101-3. Epub 2008 Jan 9.
Detection of RNA of mumps virus during an outbreak in a population with a high level of measles, mumps, and rubella vaccine coverage.
Bitsko RH, Cortese MM, Dayan GH, Rota PA, Lowe L, Iversen SC, Bellini WJ.
Source:Epidemic Intelligence Service, Office of Workforce and Career Development, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Abstract
The duration of mumps virus RNA detection was studied during a mumps outbreak in a highly vaccinated university population. Seven of the eight reverse transcription-PCR-positive specimens were collected during the first 3 days of parotitis, suggesting that viral shedding is minimal after the first 3 days of symptoms.
http://www.ncbi.nlm.nih.gov/pubmed/18184850
However, in three days, you could infect 100′s of people.
General Index: But as you can see, very few actual studies on vaccine shedding have been done.
http://www.ncbi.nlm.nih.gov/pubmed?term=shedding%20of%20measles%20vaccine%20mealses
http://www.ncbi.nlm.nih.gov/sites/entrez
Secondary Transmission: The short and sweet about live virus vaccine shedding.(A short list of the evidence of shedding in regard to each specific vaccine).
Measles Vaccine Found in Throat of Vaccinated Child
http://www.ncbi.nlm.nih.gov/pubmed/11858860
Pediatr Dermatol. 2005 Mar-Apr;22(2):130-2.
Vaccine-associated “wild-type” measles.
http://www.ncbi.nlm.nih.gov/pubmed/15804301
Acta Paediatr Jpn. 1995 Jun;37(3):374-6.
Measles encephalomyelitis in a patient with a history of vaccination.
http://www.ncbi.nlm.nih.gov/pubmed/7645392
Clin Infect Dis. 1999 Oct;29(4):855-61.
Measles inclusion-body encephalitis caused by the vaccine strain of measles virus.
http://www.ncbi.nlm.nih.gov/pubmed/10589903
Pediatr Neurol. 1999 May;20(5):399-402.
Acute disseminated encephalomyelitis with probable measles vaccine failure.
http://www.ncbi.nlm.nih.gov/pubmed/10371390
I would take my chances with natural infection and recovery, any day; over that of the use of a vaccine, or in this and the most common case, the MMR vaccine..
Treating cancer with dissimilar disease
By Dr. Guillermo Zamora, a surgeon UAG, Homeopath (Dhom. Med) by the Institute for Homoeopathic Medicine.
For those who question the strength of the inductive method of reasoning applied to medicine proposed by Hahnemann, put as an example if not its antithesis, if it is unduly partial observation of an event, the report that for several days been going on for the journal Public Library of Science Pathogens [1] and has been published in various journals, conferences, websites, and magazines [2].
This report mentions that a genetically modified virus ["oncolytic" herpes simplex virus (HSV)] has been created, and is able to block the spread of ovarian cancer and breast cancer in mice. It seems important to mention that different sources of conventional medicine, have been saying this for several years.
Chief Scientist, Professor Gabriella Campadelli-Fiume, University of Bologna in Italy, said: “Many laboratories worldwide are using more specific viruses as weapons against cancer cells, called oncolytic viruses.”
“Safety concerns prevailed so far, and all oncolytic herpes virus now in clinical trials are weakened viruses, effective only against a fraction of tumors.”
“We were the first to obtain a reprogrammed herpes virus to enter positive tumor cells, unable to infect other cells, but retains the same ability to kill in order that the wild-type HSV.”
According to Dr. Kevin Harrington, Institute of Cancer Research in London, who is leading oncolytic virotherapy studies [3], has been obtained “success” in up to 93% of cases in which the virus (and other viruses such as reovirus and adenovirus) has been modified to not infect healthy tissue (?) and according to the studies could become successful treatment in the fight against head and neck cancer.
With FDA approval, studies (including multicenter) are carried out in different phases using intratumoral injection in order to evaluate the response of colony stimulating factor-granulocyte macrophage [JS1/34.5-/47-/granulocyte -macrophage colony-stimulating factor (GM-CSF)] in different types of advanced cancer. Studies may include combinations of chemotherapy with cyclophosphamide, docetaxel, 3-AP Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone), radiation therapy, or combined chemoradiation in which studies show is “synergy” between all therapies. Side effects such as anemia, nausea, and fatigue are often reported, and neutropenia. One speaks of proviral states as vascular endothelial growth factor (vascular endothelial growth factor or VEGF) during which the reovirus can replicate oncolytic administered systemically in the endothelium, thereby inducing immune-mediated vascular collapse with significant antitumor properties.
Many studies show how are you amazing results with proven results in the treatment of certain cancers. However, the long term effects of drug-biological treatments, dependence and the tendency to acquire another disease state or immune weakness, are some maxims that should worry us. No medical intervention or treatment should be given without a long period of experimentation and testing (*). A Hahnemann It took eight years before he started dealing with Homoeopathy. There are many books, documents and writings and research experiments on the reactions, similarities, and results before he carefully follow each step with your therapy.
(*) This warning applies also for studies with the name “Homoeopathy” is conducted for cancer treatment (for example the protocol Banerji Homeopathic Research Foundation), especially when real has not been practiced homeopathy for decades for most of the “homeopathic”.
Something that has not been taken into account is that one thing is the infectious agent with whom you work for any purpose, and one is the reaction-disease so mild, moderate or severe body generates all contacts that agent. Any modified agent however, can not be discriminative enough not to cause a reaction in the center of the life force (wherever it is), as we saw with the immediate side effects reported as anemia, nausea, fatigue and neutropenia.
The experimental study is developed with the herpes virus, derived from observation (as I said at the beginning, unduly partial) that people with cancer and at the same time acquire or come into contact with people infected with the herpes virus appear stop development of its initial cancerous state, and even reverse it [4]. (I translate an extract of the reference number 4 on the history of oncolytic therapy, for the convenience of our readers)
“It seems that the use of viruses in cancer treatment was not the result of some insightful theory of alternative therapy, but rather only derived from the observation that, occasionally, cancer patients who contracted an infectious disease had brief periods clinical remission. “
So, we put a lot of attention. We must not lose the entire complex under which certain conditions are favoring the experimental subjects, who were either inmunosuprime (even when it is intended to search a localized immune response), or causes them to weaken their disease through chemo and / or radiation while trying to “attack” the tumor with the modified virus. This means that protocols require that artificially weaken, suppress or maintain and produce a susceptibility to opportunistic infectious miasm widely known, but enough to make it amended as yet unknown. With this, it will be predicted drug dependence or ultimately death because desarmonizado balance that sustains life. We will see later why.
This herpes and cancer research leads me to remember what Hahnemann had observed about through simple inductance and I would have liked to have been taken into account by the researchers (or perhaps if they knew about it?). This would comment that we do not object to people using their preferred therapy or oppose personal opinions. What we would like is that these observations are considered under Baconian establish a new era in science as applied to medicine.
I can not leave out, mention the fact that prior experimentation on animals has serious drawbacks, including:
(**) Vaccines may also be applied to the same vial containing three viruses or vaccines contaminated with unknown viruses. [5, 6.7 to cite some references, but there is enough hemerography about]
As I mentioned before and want to accept it or not researchers oncolytic viral therapy (they did not know, did not understand, did not care or did purposely. No) [4], for almost 200 years, Hahnemann had already observed in As regards to the reaction-disease, three circumstances where two dissimilar diseases coexist in the body of a human being, I quote two of those three circumstances with some of his remarks and references:
Aphorism § 38, Organon, 6th. edition
“II. – New to dissimilar disease is the strongest. – In this case the disease under which the patient lived primitively, being the weakest, will be arrested and suspended by the emergence of stronger, until it cross its course or be cured, then the old reappears uncured. ‘
The aphorism § 40, 6th Organon. Editing refers to a combined response (or response miasmatic disease combined mutant)
“III. – The new disease, after he had worked a long time in the body, finally joins that is unlike the former, and forms with it a complex disease, so that each occupies a special location in the body, ie organs peculiarly adapted to it and only that particular location belongs, while leaving the remaining organs other disease that is unlike … For two dissimilar diseases can not be destroyed, can not be cured to one another … not However, there have also been major epidemics of this kind, in which two dissimilar acute and, in rare cases, have occurred simultaneously in one and the same body, and combined, as it were, for a short time with each other … then, though not completely incurable, but can be transformed into health with very great difficulty. “
This latter circumstance applies for malnourished patients, and / or with certain addictions, and / or debilitating conditions, and / or in immunosuppressed patients, etc. A clear example of this would be all diseases “new” appearance as acquired immunodeficiency syndrome (AIDS), in which you can combine various diseases caused by two or more types of the herpes family (***) and microorganisms and other viral, bacterial, fungal, etc..
(***) In the last 100 years have discovered 8 different types of herpes.
1.-TYPE herpes simplex virus I.
2.-Herpes Simplex Virus Type II
3.-varicella-zoster virus.
4.-Epstein-Barr virus.
5.-CITAMEGALOVIRUS.
6.-herpesvirus-6-6-B AY. (HHV-6)
7.-herpesvirus 7 (HHV-7)
8.-human herpesvirus 8 (Kaposi’s sarcoma)
If we reflect the foregoing, we find that Hahnemann makes complete observations (and NO partial), deep and detailed the circumstances between two dissimilar diseases coexist, including the aftermath of the same, so we can see that the inductance in science, observe the experienced (even from the same accident or toxicity), helps predict the outcome of an event. Take into account the principles established by Hahnemann in the Organon for experimentation and the coexistence of two dissimilar diseases is not a minor thing. Accept and understand our limitations, our achievements, and the consequences of such applications in medicine is vital to our future and wellbeing.
References
[1] http://www.plospathogens.org/
[2] Huffingtonpost, Herpes Virus Could Be Key To Breast And Ovarian Cancer Treatment, The Huffington Post UK | Posted: 31/01/2013 22:16 GMT
GM virus blocks spread of cancer, Press Association – Thu, Jan 31, 2013, yahoo news.
Herpes virus, “new weapon” against cancer Join BBC Science, August 2, 2010 – 13:39 GMT
The herpes virus shows promise in treating breast cancer, Isaude, Science and Technology, published on 26/10/2011 at 13h58: 00
HERPES VIRUS SHOWS PROMISE IN TREATING EARLY TRIPLE-NEGATIVE BREAST CANCER Oncolytic viral therapy shows great potential for treating an aggressive form of breast cancer, News from the Clinical Congress, Yuman Fong, MD, FACS Sepideh Gholami, MD, Monday, October 24, 1:00 pm
[3] Donnelly, OG., Errington-Mais, F., Prestwich, R., Harrington, K., Pandha, H., Vile, R. & Melcher, AA. (2012) Recent Clinical Experience with oncolytic Viruses Current Pharmaceutical Biotechnology, Vol.13 (9), pp.1834-1841, ISSN: 1389-2010.
Adair, RA., Roulstone, V., Scott, KJ., Morgan, R., Nuovo, GJ., Fuller, M., Beirne, D., West, EJ., Jennings, VA., Rose, A., et al. (2012) Cell Carriage, Delivery, and Selective Replication of an oncolytic virus in Tumor in Patients Science Translational Medicine, Vol.4 (138), ISSN: 1946-6234.
Karapanagiotou, MS., Roulstone, V., Twigger, K., Ball, M., Tanay, M., Nutting, C., Newbold, K., Gore, ME., Larkin, J., Syrigos, KN., et al. (2012) Phase I / II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with Advanced Malignancies. Clin Cancer Res, Vol.18 (7), pp.2080-2089, ISSN: 1078-0432 .
Simpson, GR., Horvath, A., Annels, NE., Pencavel, T., Metcalf, S., Seth, R., Peschard, P., Price, T., Coffin, RS., Mostafid, H., et al. (2012) Combination of a fusogenic glycoprotein, pro-drug activation and oncolytic HSV as an intravesical therapy for bladder cancer Surface British Journal of Cancer, Vol.106 (3), pp.496-507, ISSN: 0007-0920 .
Kottke, T., Chester, J., Ilett, E., Thompson, J., Diaz, R., Coffey, M. Selby, P., Nuovo, G., Pulido, J., Mukhopadhyay, D., et al. (2011) Precise Scheduling of Chemotherapy Primes VEGF-producing Tumors for Successful Systemic oncolytic virotherapy MOL THER, Vol.19 (10), pp.1802-1812, ISSN: 1525-0016.
Heinemann, L., Simpson, GR., Boxall, A., Kottke, T., Relph, KL., Vile, R., Melcher, A., Prestwich, R., Harrington, KJ., Morgan, R., et al. (2011) Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer BMC CANCER, Vol.11 ISSN: 1471-2407.
Touchefeu, Y., Vassaux, G. & Harrington, KJ. (2011) oncolytic viruses in radiation oncology Radiother Oncol, vol.99 (3), pp.262-270, ISSN: 0167-8140.
Ilett, EJ., Barcena, M., Errington-Mais, F., Griffin, S., Harrington, KJ., Pandha, HS., Coffey, M., Selby, PJ., Limpens, RWAL., Mommaas, M . et al. (2011) Internalization of oncolytic Reovirus by Human Dendritic Cell Carriers from the Virus Neutralization Protects Clin Cancer Res, Vol.17 (9), pp.2767-2776, ISSN: 1078-0432.
Willmon, C., Diaz, RM., Wongthida, P., Galivo, F., Kottke, T., Thompson, J., Albelda, S., Harrington, K., Melcher, A. & Vile, R. (2011) Vesicular Stomatitis Virus-induced Suppressor Cells Immune Antagonism Between Intratumoral oncolytic Generate Virus and Cyclophosphamide Mol Ther, Vol.19 (1), pp.140-149, ISSN: 1525-0016.
Senzer, NN., Kaufman, HL., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) Phase II Clinical Trial of a Granulocyte-macrophage colony-stimulating factor-Encoding, Second-Generation oncolytic herpesvirus in unresectable Patients With Metastatic Melanoma J CLIN ONCOL, Vol.27 (34), pp.5763-5771, ISSN: 0732-183x.
Harrington, KJ. (2010) Topical treatment for oral Cancers Winners and Losers and oncolytic adenoviruses: who should be down in the mouth? GENE THER, Vol.17 (12), pp.1421-1422, ISSN: 0969-7128.
Harrington, KJ., Hingorani, M., Tanay, MA., Hickey, J., Bhide, SA., Clarke, PM., Renouf, LC., Thway, K., Sibtain, A., McNeish, IA., et al. (2010) Phase I / II Study of oncolytic HSVGM-CSF in Combination with Cisplatin in Untreated Radiotherapy and Stage III / IV Squamous Cell Cancer of the Head and Neck Clin Cancer Res, Vol.16 (15), pp.4005 -4015, ISSN: 1078-0432.
Merron, A., Baril, P., Martin-Duque, P., de la Vieja, A., Tran, L., Briat, A., Harrington, KJ., McNeish, IA. & Vassaux, G. (2010 ) Assessment of the Na / I symporter gene as a reporter to visualize oncolytic adenovirus propagation in peritoneal Tumours Eur J Nucl Med MOL I, Vol.37 (7), pp.1377-1385, ISSN: 1619-7070.
Kottke, T., Hall, G., Pulido, J., Diaz, RM., Thompson, J., Chong, H., Selby, P., Coffey, M., Pandha, H., Chester, J., et al. (2010) Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of tumors in mice Established J CLIN INVEST, Vol.120 (5), pp.1551-1560, ISSN: 0021-9738.
Harrington, KJ., Vile, RG., Melcher, A., Chester, J. & Pandha, HS. (2010) Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics. Cytokine Growth Factor Rev, Vol.21 (2-3), pp.91-98.
Senzer, NN., Kaufman, HL., Amatruda, T., Nemunaitis, M., Reid, T., Daniels, G., Gonzalez, R., Glaspy, J., Whitman, E., Harrington, K., et al. (2009) Phase II Clinical Trial of a Granulocyte-macrophage colony-stimulating factor-Encoding, Second-Generation oncolytic herpesvirus in unresectable Patients With Metastatic Melanoma J CLIN ONCOL, Vol.27 (34), pp.5763-5771, ISSN: 0732-183x.
Willmon, C., Harrington, K. Kottke, T., Prestwich, R. Melcher, A. & Vile, R. (2009) Cell Carriers for oncolytic Viruses: Fed Ex for Cancer Therapy MOL THER, Vol.17 (10), pp.1667-1676, ISSN: 1525-0016.
Prestwich, RJ., Errington, F., Steele, LP., Ilett, EJ., Morgan, RSM., Harrington, KJ., Pandha, HS., Selby, PJ., Vile, RG. & Melcher, AA. (2009) Reciprocal Human Dendritic Cell-Induced Natural Killer Cell Interactions Following Antitumor Activity Tumor Cell Reovirus Infection by oncolytic J Immunol, Vol.183 (7), pp.4312-4321, ISSN: 0022-1767.
Pandha, HS., Heinemann, L., Simpson, GR., Melcher, A., Prestwich, R., Errington, F., Coffey, M., Harrington, KJ. & Morgan, R. (2009) Synergistic Effects of oncolytic Reovirus and Cisplatin Chemotherapy in Murine Malignant Melanoma CLIN CANCER RES, Vol.15 (19), pp.6158-6166, ISSN: 1078-0432.
Prestwich, RJ., Errington, F., Diaz, RM., Pandha, HS., Harrington, KJ., Melcher, AA. & Vile, RG. (2009) The Case of oncolytic Viruses Versus the Immune System: Waiting on the Judgment of Solomon HUM GENE THER, Vol.20 (10), pp.1119-1132, ISSN: 1043-0342.
Prestwich, RJ., Ilett, EJ., Errington, F., Diaz, RM., Steele, LP., Kottke, T., Thompson, J., Galivo, F., Harrington, KJ., Pandha, HS., et al. (2009) Immune-Mediated Antitumor Activity of Reovirus Is Required for Therapy and Is Independent of Direct Viral Replication Oncolysis and CLIN CANCER RES, Vol.15 (13), pp.4374-4381, ISSN: 1078-0432.
Pandha, H., Melcher, A., Harrington, K. & Vile, R. (2009) oncolytic Viruses: Time to Compare, Contrast, and Combine? MOL THER, Vol.17 (6), pp.934-935, ISSN: 1525-0016.
Ilett, EJ., Prestwich, RJ., Kottke, T., Errington, F., Thompson, JM., Harrington, KJ., Pandha, HS., Coffey, M., Selby, PJ., Vile, RG., et al. (2009) Dendritic cells and T cells deliver Tumour killing oncolytic DESPITE reovirus for pre-existing anti-viral immunity Gene Ther, Vol.16 (5), pp.689-699, ISSN: 0969-7128.
Kottke, T., Thompson, J., Diaz, RM., Pulido, J., Willmon, C., Coffey, M., Selby, P., Melcher, A., Harrington, K. & Vile, RG. (2009) Improved Systemic Delivery of Established Tumors to Reovirus oncolytic Using Preconditioning with Cyclophosphamide-Mediated Treg Modulation and Interleukin-2 Clin Cancer Res, Vol.15 (2), pp.561-569, ISSN: 1078 – 0432.
Prestwich, RJ., Errington, F., Ilett, EJ., Morgan, RSM., Scott, KJ., Kottke, T., Thompson, J., Morrison, EE., Harrington, KJ., Pandha, HS., et al. (2008) Tumor Infection by oncolytic Reovirus Primes Adaptive Antitumor Immunity CLIN CANCER RES, Vol.14 (22), pp.7358-7366, ISSN: 1078-0432.
Prestwich, RJ., Harrington, KJ., Pandha, HS., Vile, RG., Melcher, AA. & Errington, F. (2008) oncolytic viruses: a novel form of immunotherapy EXPERT ANTICANC REV, Vol.8 (10), pp.1581-1588, ISSN: 1473-7140.
Harrington, KJ., Melcher, A., Vassaux, G., Pandha, HS. & Vile, RG. (2008) Exploiting Synergies Between radiation and oncolytic viruses. Curr Opin Mol Ther, Vol.10 (4), pp.362-370, ISSN: 1464-8431.
Prestwich, RJ., Harrington, KJ., Vile, RG. & Melcher, AA. (2008) immunotherapeutic potential of oncolytic virotherapy LANCET ONCOL, Vol.9 (7), pp.610-612, ISSN: 1470-2045.
Kottke, T., Galivo, F., Wongthida, P., Diaz, RM., Thompson, J., Jevremovic, D., Barber, GN., Hall, G., Chester, J., Selby, P., et al. (2008) Treg depletion-enhanced IL-2 therapy of treatment Facilitates Established tumors delivered systemically using oncolytic virus Mol Ther, Vol.16 (7), pp.1217-1226, ISSN: 1525-0016.
White, CL., Twigger, KR., Vidal, L., De Bono, JS., Coffey, M., Heinemann, L., Morgan, R., Merrick, A., Errington, F., Vile, RG. , et al. (2008) Characterization of the adaptive and innate immune response to intravenous oncolytic reovirus (Dearing type 3) during a phase I clinical trial. Gene Ther, Vol.15 (12), pp.911-920.
Qiao, J., Kottke, T., Willmon, C., Galivo, F., Wongthida, P., Diaz, RM., Thompson, J., Ryno, P., Barber, GN., Chester, J., et al. (2008) Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, immunotherapy and virotherapy oncolytic Nat Med, Vol.14 (1), pp.37-44, ISSN: 1078-8956.
Hu, JC., Coffin, RS., Davis, CJ., Graham, NJ., Groves, N., Guest, PJ., Harrington, KJ., James, ND., Love, CA., McNeish, I., et al. (2006) A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res, Vol.12 (22), pp.6737-6747, ISSN: 1078-0432.
[4] NATURE, Molecular Therapy (2007) 15 4, 651-659 doi: 10.10, “History of oncolytic Viruses: Genesis to Genetic Engineering”, Elizabeth Kelly and Stephen J Russell:
“It Appears That the use of viruses in the treatment of cancer was not the result of some perspicacious theory of an alternative therapy but Rather stemmed from the observation just That, occasionally, Contracted cancer patients who went into an infectious disease brief periods of clinical remission . “
[5] Modulation of immune responses during canine distemper virus infection: implications for therapeutic and vaccine development, Céspedes PF *, P Cruz, CO Navarro, Faculty of Veterinary and Animal Sciences, Laboratory of Animal Virology, University of Chile , Santiago, Chile. Arch Med Vet 42, 15-28 (2010):
“This last statement is based on evidence of the ability of the attenuated vaccine virus to revert to virulence so fleeting and cause lethal encephalitis in dogs following immunization and, similarly, a multisystem box of 90-100% morbidity and lethality in ferrets blacklegged (Mustela putorius furo) (Summers and Appel 1994, von Messling et al 2003). “
[6] Reverse Genetics for Live Attenuated Virus Vaccine Development Kun Yao, * and Zaishi Wang
“… An attenuated virus can still replicate in the Vaccinated Individuals, Therefore, the virus has the potential to revert to virulent phenotypes. Moreover, some of live vaccines can be Transmitted from the person to non immunized Vaccinated Individuals … “
“These are particularly important safety Concerns for Certain human RNA human parainfluenza viruses Such as virus (PIV), respiratory syncytial virus (RSV) and HIV, since viruses These RNA, RNA-dependent RNA Whose polymerases do not have a proofreading function and a high Could Occur During mutation rate virus replication. “
[7] Altered Virulence of Vaccine Strains of Measles Virus after Prolonged Replication in Human Tissue, Alexandra Valsamakis et al, J Virol. October 1999, 73 (10): 8791-8797.
Share this: